Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe webpage has removed a notice regarding heavy traffic affecting certain services and products, as well as a specific date. Additionally, a new date has been added.SummaryDifference6%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting NLM-NCBI services and products, along with a contact for assistance. Additionally, a date has been added, while a previous date has been removed.SummaryDifference7%
- Check39 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check53 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check61 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference1.0%
- Check89 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.